Zylorion

Zylorion is a biotech corporation specializing in the research and delivery of integrated precision mental health therapies for psychological and neurological mental illnesses.

Zylorion is dedicated to the study, creation, and marketing of psychedelic-based medicines combined with novel therapeutic treatment techniques for a wide range of mental health issues including MDD (major depressive disorder), TRD (treatment resistant depression), PTSD (post-traumatic stress disorder), general depression, anxiety disorders, and a number of addictive tendencies.

Zylorion is working to use cutting-edge technologies to help its integrated treatment programs scale and be accessible. In its goal of enabling individuals who are dealing with mental health issues to flourish, Zylorion is striving to apply leading technologies to support the scalability and accessibility of its integrated therapy programs.

Psychedelic News

Zylorion Announces New U.S. Patent Filing For Novel Second-Generation Psilocybin-Based Compound

Zylorion announced today the filing of the Company’s third provisional patent application with the United States Patent and Trademark Office (“USPTO”). The

July 14, 2022

Zylorion

Zylorion Announces New U.S. Patent Filing For Novel Second-Generation Psilocybin-Based Compound

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment

Suggestions

Zylorion

Zylorion Announces New U.S. Patent Filing For Novel Second-Generation Psilocybin-Based Compound

Choose Ketamine Complete Capital Raise to Expand Technology Platform

Biomind Labs Secure FDA Pre-IND Meeting for Feedback on NCE Triptax

Silo Pharma Initiate Toxicity Study of Ketamine Formulation for Fibromyalgia Treatment